Docetaxel plus cyclophosphamide is cost-effective compared to doxorubicin plus cyclophosphamide, based on an economic analysis of US oncology trial 9735: additional rationale to avoid anthracyclines in the adjuvant treatment of operable breast cancer?

被引：0
|
作者：
Verma, S.
Mittmann, N.
Bernard, L.
Thompson, M.
Chan, B.
Asmar, L.
Jones, S.
机构：
[1] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[2] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[3] Cornerstone Res Grp Inc, Burlington, ON, Canada
[4] US Oncol Res, Houston, TX USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：378S / 378S
页数：1
相关论文
共 42 条
  • [1] COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN PLUS CYCLOPHOSPHAMIDE IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER
    Jones, S.
    Chen, L.
    Tangirala, M.
    Asmar, L.
    Airia, P.
    Thompson, M. F.
    VALUE IN HEALTH, 2009, 12 (03) : A45 - A45
  • [2] LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER
    Jackson, D.
    Lee, J. M.
    Adams, J.
    Gordois, A.
    VALUE IN HEALTH, 2009, 12 (07) : A274 - A274
  • [3] Long-term survival benefits of docetaxel plus cyclophosphamide compared to doxorubicin plus cyclophosphamide in the adjuvant treatment of operable breast cancer
    Thompson, M.
    Seal, B.
    Tangirala, M.
    Asmar, L.
    Jones, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
    Jones, Stephen E.
    Savin, Michael A.
    Holmes, Frankie Ann
    O'Shaughnessy, Joyce A.
    Blum, Joanne L.
    Vukelja, Svetislava
    McIntyre, Kristi J.
    Pippen, John E.
    Bordelon, James H.
    Kirby, Robert
    Sandbach, John
    Hyman, William J.
    Khandelwal, Pankaj
    Negron, Angel G.
    Richards, Donald A.
    Anthony, Stephen P.
    Mennel, Robert G.
    Boehm, Kristi A.
    Meyer, Walter G.
    Asmar, Lina
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5381 - 5387
  • [5] Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer
    Roy, V
    Perez, EA
    CANCER TREATMENT REVIEWS, 2006, 32 (01) : 55 - 58
  • [6] US AND CANADIAN COST-EFFECTIVENESS ANALYSES OF US ONCOLOGY TRIAL 9735 PROVIDE ADDITIONAL RATIONALE FOR AVOIDING ANTHRACYCLINES IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER
    Chin, C.
    Jones, S.
    Verma, S.
    Bernard, L.
    Thompson, M. F.
    Mittmann, N.
    Chan, B. C. F.
    Tangirala, M.
    Asmar, L.
    VALUE IN HEALTH, 2009, 12 (07) : A269 - A269
  • [7] Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
    Peng Liubao
    Wan Xiaomin
    Tan Chongqing
    Karnon, Jon
    Chen Gannong
    Li Jianhe
    Cui Wei
    Luo Xia
    Cao Junhua
    PHARMACOECONOMICS, 2009, 27 (10) : 873 - 886
  • [8] Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer
    Martin, Miguel
    WOMENS HEALTH, 2006, 2 (04) : 527 - 537
  • [9] Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese PerspectiveDoxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
    Peng Liubao
    Wan Xiaomin
    Tan Chongqing
    Jon Karnon
    Chen Gannong
    Li Jianhe
    Cui Wei
    Luo Xia
    Cao Junhua
    PharmacoEconomics, 2009, 27 : 873 - 886
  • [10] Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer (vol 24, pg 5381, 2006)
    Jones
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1819 - 1819
12345